Matrine ameliorates experimental autoimmune encephalomyelitis by modulating chemokines and their receptors

Experimental and Molecular Pathology

Volumn 99, Issue 2, 2015, Pages 212-219

  Kan, Quan Cheng ^a   Pan, Qing xia ^a   Zhang, Xiao Jian ^a   Chu, Yao juan ^a   Liu, Nan ^a   Lv, Peng ^a   Zhang, Guang Xian ^b   Zhu, Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

CCL2 CCR2; Chemokine chemokine receptor; CXCL10 CXCR3; EAE MS

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CXCR3; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MATRINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; ALKALOID; CHEMOKINE; QUINOLIZINE DERIVATIVE;

ANIMAL MODEL; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DEMYELINATION; DISEASE SEVERITY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATORY CELL; MACROPHAGE; MONOCYTE; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; DRUG EFFECTS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RAT; REAL TIME POLYMERASE CHAIN REACTION; WISTAR RAT;

ALKALOIDS; ANIMALS; CHEMOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; IMMUNOENZYME TECHNIQUES; QUINOLIZINES; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84937778754     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.06.008     Document Type: Article

References (34)

1. Ajami B., Bennett J.L., Krieger C., et al. Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat. Neurosci. 2011, 14(9):1142-1149. 10.1038/nn.2887.
2. Antonelli A., Ferrari S.M., Giuggioli D., et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 2014, 13(3):272-280. 10.1016/j.autrev.2013.10.010.
3. Brini E., Ruffini F., Bergami A., et al. Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss. J. Neuroimmunol. 2009, 209(1-2):33-39. 10.1016/j.jneuroim.2009.01.022.
4. + monocyte subset during multiple sclerosis. Immunol. Cell Biol. 2014, 92(6):509-517. 10.1038/icb.2014.15.
5. Dufour J.H., Dziejman M., Liu M.T., et al. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 2002, 168(7):3195-3204. 10.4049/jimmunol.168.7.3195.
6. Elhofy A., Wang J., Tani M., et al. Transgenic expression of CCL2 in the central nervous system prevents experimental autoimmune encephalomyelitis. J. Leukoc. Biol. 2005, 77(2):229-237. 10.1189/jlb.0804465.
7. + T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 2001, 166(12):7617-7624. 10.4049/jimmunol.166.12.7617.
8. Gao L., Tang H., Nie K., et al. MCP-1 and CCR2 gene polymorphisms in Parkinson's disease in a Han Chinese cohort. Neurol. Sci. 2014, 36(4):571-576. 10.1007/s10072-014-1990-3.
9. Guo M.F., Meng J., Li Y.H., et al. The inhibition of Rho kinase blocks cell migration and accumulation possibly by challenging infl ammatory cytokines and chemokines on astrocytes. J. Neurol. Sci. 2014, 343(1-2):69-75. 10.1016/j.jns.2014.05.034.
10. Huang D.R., Wang J., Kivisakk P., et al. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J. Exp. Med. 2001, 193(6):713-725. 10.1084/jem.193.6.713.
11. Ko E.M., Ma J.H., Guo F.Z., et al. Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model. J. Neuroinflammation 2014, 11:105. 10.1186/1742-2094-11-105.
12. Liu M., Liu X.Y., Cheng J.F. Advance in the pharmacological research on matrine. China J. Chin. Mater. Med. 2003, 28(9):801-804.
13. Liu N., Kan Q.C., Zhang X.J., et al. Upregulation of immunomodulatory molecules by matrine treatment in experimental autoimmune encephalomyelitis. Exp. Mol. Pathol. 2014, 97(3):470-476. 10.1016/j.yexmp.2014.10.004.
14. Mahad D.J., Ransohoff R.M. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin. Immunol. 2003, 15(1):23-32. 10.1016/S1044-5323(02)00125-2.
15. Mahad D., Callahan M.K., Williams K.A., et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 2006, 129(Pt 1):212-223. 10.1093/brain/awh655.
16. Mandal R.K., Agrawal T., Mittal R.D. Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer. Tumor Biol. 2015, 36(1):375-381. 10.1007/s13277-014-2646-x.
17. Mishra M.K., Wang J., Silva C., et al. Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod. Am. J. Pathol. 2012, 181(2):642-651. 10.1016/j.ajpath.2012.05.011.
18. Miyagishi R., Niino M., Fukazawa T., et al. C-C chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J. Neuroimmunol. 2003, 145(1-2):135-138. 10.1016/j.jneuroim.2003.09.003.
19. Prins M., Dutta R., Baselmans B., et al. Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of multiple sclerosis patients. Acta Neuropathol. Commun. 2014, 2:98. 10.1186/s40478-014-0098-6.
20. Romagnani P., Crescioli C. CXCL10: A candidate biomarker in transplantation. Clin. Chim. Acta 2012, 413(17-18):1364-1373. 10.1016/j.cca.2012.02.009.
21. Sellebjerg F., Sørensen T.L. Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system. Brain Res. Bull. 2003, 61(3):347-355. 10.1016/S0361-9230(03)00097-2.
22. Semple B.D., Kossmann T., Morganti-Kossmann M.C. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. J. Cereb. Blood Flow Metab. 2010, 30(3):459-473. 10.1038/jcbfm.2009.240.
23. Shi D., Zhang J., Qiu L., et al. Matrine inhibits infiltration of the inflammatory Gr1(hi) monocyte subset in injured mouse liver through inhibition of monocyte chemoattractant protein-1. Evid. Based Complement. Alternat. Med. 2013, 2013:580673. 10.1155/2013/580673.
24. Sørensen T.L., Tani M., Jensen J., et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J. Clin. Invest. 1999, 103(6):807-815. 10.1172/JCI5150.
25. Sørensen T.L., Trebst C., Kivisakk P., et al. Multiple sclerosis: a study of CXCL10 and CXCR3 co-localization in the inflamed central nervous system. J. Neuroimmunol. 2002, 127(1-2):59-68. 10.1016/S0165-5728(02)00097-8.
26. Stamatovic S.M., Shakui P., Keep R.F., et al. Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J. Cereb. Blood Flow Metab. 2005, 25(5):593-606. 10.1038/sj.jcbfm.9600055.
27. Suo Z., Liu Y., Ferreri M., et al. Impact of matrine on inflammation related factors in rat intestinal microvascular endothelial cells. J. Ethnopharmacol. 2009, 125(3):404-409. 10.1016/j.jep.2009.07.023.
28. Szczucinski A., Losy J. Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies. Acta Neurol. Scand. 2007, 115(3):137-146. 10.1111/j.1600-0404.2006.00749.x.
29. Wong M.M., Fish E.N. Chemokines: attractive mediators of the immune response. Semin. Immunol. 2003, 15(1):5-14. 10.1016/S1044-5323(02)00123-9.
30. Yao Y.And, Tsirka S.E. Monocyte chemoattractant protein-1 and the blood-brain barrier. Cell. Mol. Life Sci. 2014, 71(4):683-697. 10.1007/s00018-013-1459-1.
31. Zhang G.X., Gran B., Yu S., et al. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. J. Immunol. 2003, 170(4):2153-2160. 10.4049/jimmunol.170.4.2153.
32. Zhang F., Wei W., Chai H., et al. Aurintricarboxylic acid ameliorates experimental autoimmune encephalomyelitis by blocking chemokine-mediated pathogenic cell migration and infiltration. J. Immunol. 2013, 190(3):1017-1025. 10.4049/jimmunol.1201994.
33. Zhang S., Kan Q.C., Xu Y., et al. Inhibitory effect of matrine on blood-brain barrier disruption f or the treatment of experimental autoimmune encephalomyelitis. Mediat. Inflamm. 2013, 736085. 10.1155/2013/736085.
34. Zhao X., Kan Q., Zhu L., et al. Matrine suppresses production of IL-23/IL-17 and ameliorates experimental autoimmune encephalomyelitis. Am. J. Chin. Med. 2011, 39(5):933-941. 10.1142/S0192415X11009317.